Patents Assigned to Wistar Institute
  • Patent number: 5573925
    Abstract: The present invention provides p53 proteins with altered tetramerization domains that retain wild-type p53 function, and the ability to form tetramers and have at least one of the following characteristics: (1) do not hetero-oligomerize with wild-type p53 or tumor-derived p53 mutants, and (2) restricted DNA binding specificity from an alteration in the way that the tetramerization domain orients the DNA binding domains of a p53 tetramer relative to one another. The invention also provides nucleic acids encoding the above proteins and methods of enhancing the cellular response to DNA damaging agents, treating diseases characterized by abnormal cell proliferation, and inducing immune tolerance to facilitate transplants and treatment of autoimmune disease, by administration of proteins of the invention or nucleic acid sequences encoding the proteins of the invention.
    Type: Grant
    Filed: November 28, 1994
    Date of Patent: November 12, 1996
    Assignee: The Wistar Institute of Anatomy and Biology
    Inventor: Thanos D. Halazonetis
  • Patent number: 5571515
    Abstract: Improved vaccine compositions and methods of making the compositions are provided, which vaccines are characterized by an antigen from a pathogen and an effective adjuvanting amount of Interleukin-12 (IL-12). These IL-12 adjuvanted vaccines are capable of increasing the vaccinated host's cell mediated immune response to provide an increased and protective immune response to the pathogen. Also disclosed are methods for vaccinating hosts by administering a vaccine containing an antigen from a pathogenic microorganism and co-administering an adjuvanting amount of IL-12. Vaccines or therapeutic compositions directed against a cancer may also be adjuvanted with IL-12 according to this invention.
    Type: Grant
    Filed: June 17, 1994
    Date of Patent: November 5, 1996
    Assignees: The Wistar Institute of Anatomy & Biology, The Trustees of the University of Pennsylvania
    Inventors: Phillip Scott, Giorgio Trinchieri
  • Patent number: 5556744
    Abstract: The present invention provides a panel of HIV peptides useful in diagnosing whether or not a patient is of vertical HIV transmission status, methods for diagnosing same, methods for identifying epitopes and peptides associated with non-transmission status, and pharmaceutical and vaccine compositions containing same.
    Type: Grant
    Filed: March 24, 1994
    Date of Patent: September 17, 1996
    Assignees: The Trustees of the University of Pennsylvania, The Wistar Institute of Anatomy & Biology
    Inventors: David B. Weiner, Kenneth E. Ugen, William V. Williams
  • Patent number: 5552143
    Abstract: The present invention provides a non-defective adenovirus recombinant expression system for the expression of the HCMV gB subunit, an immunogenic fragment of the gB subunit, and for the expression of non-structural immediate-early exon 4 proteins, said recombinant HCMV-expressing adenovirus being useful as a vaccine.
    Type: Grant
    Filed: December 2, 1994
    Date of Patent: September 3, 1996
    Assignees: The Wistar Institute of Anatomy & Biology, The United States of America as represented by the Department of Health and Human Services
    Inventors: Stanley A. Plotkin, Robert P. Ricciardi, Ewa Gonczol, Klara Berencsi, Robert F. Rando
  • Patent number: 5523393
    Abstract: The sequence of the protein coding regions of the bcl-2 gene are provided as well as bacterial clones which produce the proteins. Assays are provided for detecting a class of B-cell neoplasms associated with a chromosome translocation between chromosomes 14 and 18. This translocation is involved in the majority of cases of human follicular lymphomas. One assay employs an antibody which is immunoreactive with a human protein which is over-expressed due to the chromosome translocation. Another assay involves measurement of the amount of mRNA which hybridizes to the gene proximal to the translocation break-point.
    Type: Grant
    Filed: May 5, 1995
    Date of Patent: June 4, 1996
    Assignee: The Wistar Institute
    Inventors: Yoshihide Tsujimoto, Carlo A. Croce
  • Patent number: 5506344
    Abstract: The sequence of the protein coding regions of the bcl-2 gene are provided as well as bacterial clones which produce the proteins. Assays are provided for detecting a class of B-cell neoplasms associated with a chromosome translocation between chromosomes 14 and 18. This translocation is involved in the majority of cases of human follicular lymphomas. One assay employs an antibody which is immunoreactive with a human protein which is over-expressed due to the chromosome translocation. Another assay involves measurement of the amount of mRNA which hybridizes to the gene proximal to the translocation break-point.
    Type: Grant
    Filed: May 5, 1995
    Date of Patent: April 9, 1996
    Assignee: The Wistar Institute
    Inventors: Yoshihide Tsujimoto, Carlo A. Croce
  • Patent number: 5470571
    Abstract: Monoclonal antibody 425 having properties particularly beneficial for anti-tumor therapy has been raised. MAb 425 antibody binds to EGF-receptors and inhibits their bioactivities. The amount of binding of the antibody to cancer cells can be increased by treatment of the cells with lymphokine preparations. Radiolabeled MAb 425 is used for treatment of EGF receptor-expressing gliomas.
    Type: Grant
    Filed: April 24, 1990
    Date of Patent: November 28, 1995
    Assignee: The Wistar Institute
    Inventors: Meenhard Herlyn, Ulrich Rodeck
  • Patent number: 5459251
    Abstract: The sequence of the protein coding regions of the bcl-2 gene are provided as well as bacterial clones which produce the proteins. Assays are provided for detecting a class of B-cell neoplasms associated with a chromosome translocation between chromosomes 14 and 18. This translocation is involved in the majority of cases of human follicular lymphomas. One assay employs an antibody which is immunoreactive with a human protein which is over-expressed due to the chromosome translocation. Another assay involves measurement of the amount of mRNA which hybridizes to the gene proximal to the translocation break-point.
    Type: Grant
    Filed: April 18, 1994
    Date of Patent: October 17, 1995
    Assignee: The Wistar Institute
    Inventors: Yoshihide Tsujimoto, Carlo A. Croce
  • Patent number: 5296348
    Abstract: The present invention provides a method for selecting from among many monoclonal antibodies capable of binding to a surface antigen on a tumor cell, the antibody which also can internalize into the cell and exert an appropriate molecular effect on the level of gene regulation in the tumor cell. Such antibodies can most effectively be employed to damage the tumor cell.
    Type: Grant
    Filed: May 16, 1989
    Date of Patent: March 22, 1994
    Assignee: The Wistar Institute of Anatomy and Biology
    Inventors: Ewa Rakowicz-Szulczynska, Hilary Koprowski
  • Patent number: 5272082
    Abstract: The invention provides cytotoxic T-ALL cell lines, and modified cytotoxic T-ALL cell lines which contain a heterologous DNA sequence. The DNA sequence may encode a product capable of stabilizing or potentiating the tumoricidal activity of the cytotoxic cell lines and a product capable of controlling the growth of the cell line. Methods for use of these cell lines are also provided.
    Type: Grant
    Filed: March 30, 1992
    Date of Patent: December 21, 1993
    Assignee: The Wistar Institute of Anatomy & Biology
    Inventors: Daniela Santoli, Giovanni Rovera, Alessandra Cesano
  • Patent number: 5246921
    Abstract: A novel ribozyme, capable of selectively cleaving the bcr-abl mRNA of a cell containing the Philadelphia Chromosome, thereby blocking synthesis of BCR-ABL protein is provided. Methods for using the ribozyme for treating leukemia patients and methods of producing the ribozymes are also provided.
    Type: Grant
    Filed: August 5, 1992
    Date of Patent: September 21, 1993
    Assignee: The Wistar Institute of Anatomy and Biology
    Inventors: Premkumar Reddy, Scott Shore
  • Patent number: 5225535
    Abstract: A lymphokine is taught which can be used to activate and stimulate CD3.sup.+, CD4.sup.+ T cells, as well as Sezary leukemic T cells. The lymphokine can be obtained from mitogen-stimulated peripheral blood mononuclear cells or urine of Sezary Syndrome patients. The lymphokine upregulates interleukin-2 receptors.
    Type: Grant
    Filed: December 10, 1990
    Date of Patent: July 6, 1993
    Assignee: The Wistar Institute
    Inventors: Elaine C. DeFreitas, J. Todd Abrams
  • Patent number: 5202429
    Abstract: The sequence of the protein coding regions of the bcl-2 gene are provided as well as bacterial clones which produce the proteins. Assays are provided for detecting a class of B-cell neoplasms associated with a chromosome translocation between chromosomes 14 and 18. The translocation is involved in the majority of cases of human follicular lymphomas. One assay employs an antibody which is immunoreactive with a human protein which is over-expressed due to the chromosome translocation. Another assay involves measurement of the amount of mRNA which hybridizes to the gene proximal to the translocation break-point.
    Type: Grant
    Filed: March 19, 1991
    Date of Patent: April 13, 1993
    Assignee: The Wistar Institute
    Inventors: Yoshihide Tsujimoto, Carlo A. Croce
  • Patent number: 5185254
    Abstract: A tumor-associated antigen, GA733-1, has been discovered which shares sequence homology with both thyroglobulin type I and interleukin-2 receptors. The antigen is highly expressed in pancreatic carcinoma cells. The antigen is similar to a previously described tumor-associated antigen found in colorectal carcinoma cells. The gene for the antigen is fully sequenced and described here.
    Type: Grant
    Filed: December 29, 1988
    Date of Patent: February 9, 1993
    Assignee: The Wistar Institute
    Inventor: Alban Linnenbach
  • Patent number: 5182192
    Abstract: The present invention is directed to in vitro and in vivo immunodiagnosis and immunotherapy using monoclonal antibodies reactive with difucosyl blood group antigens Y-6 and B-7-2.
    Type: Grant
    Filed: August 6, 1990
    Date of Patent: January 26, 1993
    Assignee: The Wistar Institute
    Inventors: Zenon Steplewski, Hilary Koprowski, Magdalena Thurin
  • Patent number: 5169775
    Abstract: The present invention is directed to monoclonal antibodies, and hybridomas which produce them, which are preferentially reactive with canine lymphoma cells and insignificantly reactive with normal canine lymphocytes.
    Type: Grant
    Filed: June 29, 1990
    Date of Patent: December 8, 1992
    Assignee: The Wistar Institute
    Inventors: Zenon Steplewski, K. Ann Jeglum
  • Patent number: 5130127
    Abstract: A therapeutic method for treating human tumors in vivo is provided wherein lentinan is administered to the patient followed by treatment with anti-tumor monoclonal antibodies.
    Type: Grant
    Filed: May 28, 1991
    Date of Patent: July 14, 1992
    Assignee: The Wistar Institute
    Inventor: Dorothee Herlyn
  • Patent number: 5100774
    Abstract: Methods are provided for the detection of the synthesis of growth factor receptors or cell surface antigens by tumor cells, and for the isolation thereof.
    Type: Grant
    Filed: April 22, 1988
    Date of Patent: March 31, 1992
    Assignee: The Wistar Institute of Anatomy & Biology
    Inventor: Ewa Rakowicz-Szulczynska
  • Patent number: 5079147
    Abstract: Novel DNA sequences located 5' to the chromosome 11p13 breakpoint are employed as diagnostic probes for breast cancers, T cell leukemias and WAGR associated with chromosome 11 abnormalities. Probe compositions and methods for diganostic assays are provided.
    Type: Grant
    Filed: March 13, 1989
    Date of Patent: January 7, 1992
    Assignee: The Wistar Institute of Anatomy and Biology
    Inventors: Louise C. Showe, Richard C. Harvey
  • Patent number: 5015568
    Abstract: The sequence of the protein coding regions of the bcl-2 gene are provided as well as bacterial clones which produce the proteins. Assays are provided for detecting a class of B-cell neoplasms associated with a chromosome translocation between chromosomes 14 and 18. This translocation is involved in the majority of cases of human follicular lymphomas. One assay employs an antibody which is immunoreactive with a human protein which is over-expressed due to the chromosome translocation. Another assay involves measurement of the amount of mRNA which hybridizes to the gene proximal to the translocation break-point.
    Type: Grant
    Filed: July 9, 1986
    Date of Patent: May 14, 1991
    Assignee: The Wistar Institute
    Inventors: Yoshihide Tsujimoto, Carlo A. Croce